INmune Bio Inc.
INMB
Positions held
Your positionsINMB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $50.79M | Enterprise value | $33.78M | Trailing P/E | — | Forward P/E | -4.26 |
| PEG | — | Price / book | 2.49 | Beta | 0.90 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -74.8% | ROA | -39.1% | Debt / equity | 0.07 |
| Current ratio | 4.04 | Free cash flow | -$10.05M | Analyst recommendation | strong_buy | Mean target | $7.00 |
| 52w high | $2.60 | 52w low | $1.09 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$1.3M | -$5.4M | -$5.3M | -$6.5M | -$24.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.5M | -$5.8M | -$5.5M | -$7.4M | -$8.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.1M | $0.0M | $0.2M | $0.4M |
| Op margin | -61738.0% | -304535.7% | -19187.7% | -6938.8% |
| Net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$30.9M | -$42.6M | -$29.7M | -$26.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · INmune Bio to Attend the 2026 Maxim Growth Summit
2026-09-14 · INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
2026-09-09 · INmune Bio to Present at the H.C. Wainwright Global Investment Conference
2026-08-26 · INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
2026-08-07 · INmune Bio (INMB) Q2 2026 Earnings Call Transcript
2026-08-07 · INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...
2026-08-07 · INmune Bio, Inc. Q2 2026 Earnings Call Summary
2026-08-07 · INmune Bio Q2 Earnings Call Highlights
2026-08-06 · INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
2026-07-31 · INmune Bio Receives R&D Rebates of Approximately $4.6 Million
2026-07-31 · INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
Price (daily)
Full chart · RSI · MACD · patterns